Latest inflammatory bowel diseases Stories
PTG-100, a Novel Peptide as an 'Oral Targeted Therapy' for Inflammatory Bowel Diseases MILPITAS, Calif., Dec.
Nutraceutical Manufacturer, GI for Life, recommends Vitamin D testing after new study highlights increased risk of cancer in individuals with IBD and low plasma 25-hydroxy vitamin D (25[OH]D)
Reportbuyer.com just published a new market research report:
A statistical model accounting for dozens of different genes in combination—and the interactions between them—is an important step forward in understanding the genetic factors affecting the risk of Crohn's disease (CD).
Scientists have found a master regulator gene needed for the development of M cells, a mysterious type of intestinal cell involved in initiating immune responses.
Researchers at Baylor College of Medicine and Texas Children's Hospital have identified commensal bacteria in the human intestine that produce a neurotransmitter that may play a role in preventing or treating inflammatory bowel diseases such as Crohn's disease.
Researchers from Boston University School of Medicine (BUSM), along with clinicians from Boston Medical Center (BMC), have found gastroenterologist knowledge of the appropriate immunizations to recommend to the inflammatory bowel disease (IBD) patient is limited.
Researchers from Boston University School of Medicine (BUSM) have for the first time shown that reduced vitamin D absorption in patients with quiescent Crohn's disease (CD) may be the cause for their increased risk for vitamin D deficiency.
Researchers at the Georgia Institute of Technology and Emory University have developed a novel approach for delivering small bits of genetic material into the body to improve the treatment of inflammatory bowel diseases.
Young people with inflammatory bowel diseases have low bone mass and poor bone architecture compared to healthy people of the same age, placing them at increased risk of fracture.